Bausch & Lomb Corp BLCO
We take great care to ensure that the data presented and summarized in this overview for Bausch & Lomb Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLCO
View all-
Maple Rock Capital Partners Inc. Toronto, A63.62MShares$65.1 Million2.04% of portfolio
-
Icahn Carl C Sunny Isles Beach, FL3.5MShares$63 Million0.69% of portfolio
-
Goldentree Asset Management LP New York, NY3.36MShares$60.4 Million5.89% of portfolio
-
Alberta Investment Management Corp Edmonton, A02.21MShares$39.8 Million0.42% of portfolio
-
River Road Asset Management, LLC2.02MShares$36.4 Million0.54% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.91MShares$34.5 Million0.03% of portfolio
-
Apollo Management Holdings, L.P. New York, NY1.38MShares$24.8 Million0.39% of portfolio
-
Nomura Holdings Inc Tokyo, M01.26MShares$22.6 Million0.06% of portfolio
-
Whitebox Advisors LLC Minneapolis, MN1.24MShares$22.4 Million1.23% of portfolio
-
Empyrean Capital Partners, LP Los Angeles, CA1.24MShares$22.3 Million1.19% of portfolio
Latest Institutional Activity in BLCO
Top Purchases
Top Sells
About BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Insider Transactions at BLCO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,134
+2.27%
|
$21,546
$19.29 P/Share
|
Sep 30
2024
|
Russel C Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,328
+2.95%
|
$25,232
$19.29 P/Share
|
Aug 05
2024
|
Brent L Saunders CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
32,250
+4.89%
|
-
|
Aug 05
2024
|
Brent L Saunders CEO and Chairman of the Board |
BUY
Open market or private purchase
|
Direct |
32,250
+5.14%
|
$483,750
$15.66 P/Share
|
Aug 02
2024
|
Russel C Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+25.75%
|
-
|
Aug 02
2024
|
Thomas W. Ross Sr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+26.84%
|
-
|
Aug 02
2024
|
Andrew C. Von Eschenbach Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+26.84%
|
-
|
Aug 02
2024
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+23.54%
|
-
|
Aug 02
2024
|
Karen Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+45.88%
|
-
|
Aug 02
2024
|
Nathalie D. Bernier Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+22.96%
|
-
|
Aug 02
2024
|
Gaoxiang Hu Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+26.48%
|
-
|
Aug 02
2024
|
Brett Icahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+26.48%
|
-
|
Aug 02
2024
|
Sarah B Kavanagh Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,696
+30.58%
|
-
|
Jul 25
2024
|
Luc Bonnefoy President,Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
2,144
-3.75%
|
$32,160
$15.53 P/Share
|
Jul 25
2024
|
Frederick Munsch SVP, Controller and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,313
-2.3%
|
$19,695
$15.53 P/Share
|
Jul 25
2024
|
Sam Eldessouky EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,113
-2.1%
|
$76,695
$15.53 P/Share
|
Jul 25
2024
|
Yehia Hashad EVP of R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,841
-2.78%
|
$42,615
$15.53 P/Share
|
Jun 28
2024
|
Russel C Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,764
+5.99%
|
$24,696
$14.52 P/Share
|
Jun 28
2024
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,506
+4.36%
|
$21,084
$14.52 P/Share
|
Jun 14
2024
|
Luc Bonnefoy President,Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-1.65%
|
$14,370
$15.09 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 528K shares |
---|---|
Open market or private purchase | 32.3K shares |
Payment of exercise price or tax liability | 35.2K shares |
---|